Attovia Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Attovia Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $31.00K, a 68.37% decline year-over-year.
- Attovia Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $11.00K, a 75.56% decline year-over-year.
- Attovia Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $98.00K.
- Attovia Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $45.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $31.00K 10-Q · filed 2026-09-02 | |
| 2026-03-31 | $11.00K 10-Q · filed 2026-09-02 | |
| 2025-06-30 | $98.00K 10-Q · filed 2026-09-02 | |
| 2025-03-31 | $45.00K 10-Q · filed 2026-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |